There are 2789 resources available
Polling 2 (led by chair)
Presenter: Nicolas Girard
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast
Q&A
Presenter: Nicolas Girard
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Nicolas Girard
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast
Yes
Presenter: Heather Wakelee
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast
Clinical benefit from a patient’s perspective
Presenter: Bettina Ryll
Session: Does my patient really benefit from my treatment? Physician, patient and value perspectives
Resources:
Slides
Webcast
The ten cancer therapeutics that front-line cancer physicians find most essential
Presenter: Christopher Booth
Session: WHO access to meaningful medicines
Resources:
Slides
Webcast
ESMO’s reimbursement model
Presenter: Panagiotis Kanavos
Session: WHO access to meaningful medicines
Resources:
Slides
Webcast
Staring through the window-of-opportunity: Phase 0 trials in oncology
Presenter: Emiliano Calvo
Session: YO Masterclass: Reshaping the future of clinical trials in oncology
Resources:
Slides
Webcast
Real-world experience using the ESMO-MCBS in clinical practice
Presenter: Barbara Kiesewetter-Wiederkehr
Session: Does my patient really benefit from my treatment? Physician, patient and value perspectives
Resources:
Slides
Webcast
When does statistical significance become clinically relevant?
Presenter: Mike Clarke
Session: Does my patient really benefit from my treatment? Physician, patient and value perspectives
Resources:
Slides
Webcast